Abstract
Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Current Gene Therapy
Title:Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Volume: 16 Issue: 6
Author(s): Yingzhe Jiang, Bing Xia, Yizhuo Zhang*Wen Xu
Affiliation:
- Tianjin Medical University Cancer Institute and Hospital, 1 Huanhuxi Road, Hexi District, Tianjin 300060,China
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Abstract: Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Export Options
About this article
Cite this article as:
Jiang Yingzhe, Xia Bing, Zhang Yizhuo*, Xu Wen, Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170215154755
DOI https://dx.doi.org/10.2174/1566523217666170215154755 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Editorial(Hot Topic:Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future Directions)
Current Pharmaceutical Design Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) Editorial [Hot Topic: Innovative Therapeutical Approaches for Hematological Malignancies Based on Molecular Targeted Therapies (Executive Editor: Giorgio Zauli) ]
Current Pharmaceutical Design Chromosomal Translocations in Hematologic Malignancies
Current Genomics Stromal Derived Growth Factor-1alpha as a Beacon for Stem Cell Homing in Development and Injury
Current Neurovascular Research A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design The Nuclear Orphan Receptor NR4A1 and NR4A3 as Tumor Suppressors in Hematologic Neoplasms
Current Drug Targets Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Detection of Clonal Immunoglobulin and T-Cell Receptor Gene Recombination in Hematological Malignancies: Monitoring Minimal Residual Disease
Cardiovascular & Hematological Disorders-Drug Targets Primary Lung Lymphoma
Current Drug Targets - Inflammation & Allergy